Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study)
Launched by TAMPERE UNIVERSITY HOSPITAL · Jan 22, 2024
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
The LS-URO Study is a clinical trial aimed at finding better ways to detect urothelial cancer, which includes bladder cancer, in people with Lynch syndrome. Lynch syndrome is a genetic condition that increases the risk of several types of cancer, including urothelial cancers. This study will use a new test that looks for cancer DNA in urine to see if it can help find these cancers early, even before any symptoms appear. Early detection is important because it can lead to more effective treatment.
To participate in this study, individuals need to be between 50 and 75 years old, have been diagnosed with Lynch syndrome, and be willing to give their consent to join. People who currently have urothelial cancer cannot take part in this trial. If someone is eligible and joins the study, they can expect to provide urine samples that will be tested for cancer DNA. This research hopes to improve cancer screening for those at high risk, potentially leading to better outcomes for patients with Lynch syndrome.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Willing and able to provide informed consent
- • Diagnosis of Lynch syndrome
- • Age 50 - 75 years at study recruitment
- Exclusion Criteria:
- • Concurrent urothelial carcinoma
About Tampere University Hospital
Tampere University Hospital (TAYS) is a leading academic medical center in Finland, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, TAYS integrates cutting-edge medical practices with rigorous scientific investigation, focusing on improving patient outcomes and enhancing treatment modalities across various specialties. The hospital collaborates with a network of researchers, healthcare professionals, and academic institutions to foster a multidisciplinary approach to medical research, ensuring that findings are translated into real-world applications for the benefit of patients and the broader healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, , Canada
Tampere, , Finland
Patients applied
Trial Officials
Jussi Nikkola, MD, PhD
Principal Investigator
Tampere University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported